Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.
Here's what we know so far about the IPO, including how to buy in when the stock goes public.
|Latest market close||$37.54|
|52-week range||$23.62 - $45.79|
|50-day moving average||$41.36|
|200-day moving average||$36.26|
|Wall St. target price||$50.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-16)||N/A|
|1 month (2021-06-25)||-12.08%|
|3 months (2021-04-27)||-1.11%|
|6 months (2021-01-23)||N/A|
|1 year (2020-07-23)||N/A|
|2 years (2019-07-23)||N/A|
|3 years (2018-07-23)||N/A|
|5 years (2016-07-23)||N/A|
Valuing Maravai LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Maravai LifeSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Maravai LifeSciences shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Maravai LifeSciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Maravai LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $206 million.
The EBITDA is a measure of a Maravai LifeSciences's overall financial performance and is widely used to measure a its profitability.
To put Maravai LifeSciences's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$381.3 million|
|Operating margin TTM||47.31%|
|Gross profit TTM||$204.4 million|
|Return on assets TTM||7.02%|
|Return on equity TTM||52.65%|
|Market capitalisation||$10.8 billion|
TTM: trailing 12 months
There are currently 4.9 million Maravai LifeSciences shares held short by investors – that's known as Maravai LifeSciences's "short interest". This figure is 1.2% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting Maravai LifeSciences shares can be evaluated.
Maravai LifeSciences's "short interest ratio" (SIR) is the quantity of Maravai LifeSciences shares currently shorted divided by the average quantity of Maravai LifeSciences shares traded daily (recently around 1.3 million). Maravai LifeSciences's SIR currently stands at 3.62. In other words for every 100,000 Maravai LifeSciences shares traded daily on the market, roughly 3620 shares are currently held short.
To gain some more context, you can compare Maravai LifeSciences's short interest ratio against those of similar companies.
However Maravai LifeSciences's short interest can also be evaluated against the total number of Maravai LifeSciences shares, or, against the total number of tradable Maravai LifeSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Maravai LifeSciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Maravai LifeSciences shares in existence, roughly 20 shares are currently held short) or 0.0547% of the tradable shares (for every 100,000 tradable Maravai LifeSciences shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Maravai LifeSciences.
Find out more about how you can short Maravai LifeSciences stock.
We're not expecting Maravai LifeSciences to pay a dividend over the next 12 months.
You may also wish to consider:
Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.